News | Radiopharmaceuticals and Tracers | December 28, 2016

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmacopeia (USP) recommendations for compounded sterile radiopharmaceuticals. The recommendations aim to address certain common practices in the field of nuclear pharmacy that are not adequately defined by generally accepted practice standards. The society believes there is confusion in the field of nuclear pharmacy, which threatens the availability and the safe usage of radiopharmaceuticals in the United States. The recommendations are a response to these challenges.

The recommendations were developed by SNMMI's Committee on Radiopharmaceuticals (COR) and approved by SNMMI's Board of Directors. The COR worked with several professional organizations and trade associations in an attempt to rectify the situation. Our efforts to date have met with some success, but have still fallen short of realizing suitable standards that are generally accepted for common practices in nuclear pharmacy. The COR believes that the USP, as the world’s leading organization for the development and maintenance of public standards, can play a critical role in the resolution of these challenges.

There are three recommendations detailed in a SNMMI white paper: 

1. Establish an expert panel to delineate common practices that are defined as sterile compounding within the practice of nuclear pharmacy.
2. Create a public standard for the preparation, compounding, and dispensing of sterile radiopharmaceuticals with the practice of nuclear pharmacy.
3. Reinstate an expert committee dedicated to all standards for radiopharmaceuticals.

On September 29, SNMMI President Sally Schwarz sent the letter to the USP, where it is currently under consideration. Further details will be provided as they become available.

Access the complete document at http://snmmi.files.cms-plus.com/SNMMI-USP-Recommendations-Final_2016.pdf

Related Content

News | Nuclear Imaging

April 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear ...

Home April 13, 2022
Home
Videos | Nuclear Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Home June 02, 2021
Home
News | Nuclear Imaging

April 1, 2021 – The ability to measure myocardial blood flow (MBF) as part of myocardial perfusion imaging (MPI) is one ...

Home April 01, 2021
Home
News | Nuclear Imaging

December 4, 2020 — Spectrum Dynamics Medical, Inc., has received Canadian Medical Device License from Health Canada for ...

Home December 04, 2020
Home
News | Nuclear Imaging

September 30, 2020 — Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine ...

Home October 07, 2020
Home
Feature | Nuclear Imaging | Dave Fornell, Editor

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September ...

Home November 22, 2019
Home
Videos | Nuclear Imaging

Rob Beanlands, M.D., FASNC, 2019 American Society of Nuclear Cardiology (ASNC) president, shares a couple trends he sees ...

Home November 07, 2019
Home
Videos | Nuclear Imaging

Robert C. Hendel, M.D., explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at ...

Home November 06, 2019
Home
Feature | Nuclear Imaging | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS

Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the ...

Home July 22, 2019
Home
Subscribe Now